New name reflects venture capital firm’s international expansion as group of entrepreneur-investors adding value in biotech
Name change follows launch of second fund in September 2021 with first close at €86M aimed at building tomorrow’s most promising biotech start-ups
MANTIS (Multiplex ANnotated Tissue Imaging System) was developed at Infinity (Inserm U1291, France) by Dr. Nicolas Gaudenzio and his team; Dr. Gaudenzio was recently appointed as Genoskin’s Chief Scientific Officer (CSO)
Genoskin licensed intellectual property from Inserm to develop MANTIS as a spatial biology platform dedicated to skin immunology and to characterizing drug effects on human skin
• Largest acquisition in history of Spanish biotechnology sector and largest operation to date for Caixa Capital Risc
• Holding 20% of the capital, Caixa Capital Risc is Sanifit’s biggest stakeholder and has supported company since 2006, participating in all financing rounds for a total investment of over €23M
B2 cohort (high dose added to anti-PD-1) of the PDC-LUNG-101 trial with PDC*lung01 therapeutic cancer vaccine candidate for non-small cell lung cancer has been opened and first patients were dosed
Led by Biomunex alongside Institut Curie and GTP Bioways, with a total budget of €5.6 million, BiXAb5 non-conventional T cell redirection project seeks to create breakthrough immunotherapy approach to cancer treatment based on bispecific antibodies
German-based startup attracts venture funding from leading European VC firms to address ‘Agitation/Aggression’ in Alzheimer’s disease
• Strong first closing confirms relevance of AFB’s unique early-stage investment strategy; aiming to create, develop and finance promising European life sciences startups in innovative therapeutics
• Since 2017, AFB’s €68M ($80M) first fund – Advent France Biotechnology Seed-Fund I – has successfully financed 15 startups in France, Spain, Belgium and Ireland